期刊文献+

非小细胞肺癌的预后因素及多变量分析 被引量:6

Mulivariate analysis of prognostic factors in non small cell lung cancer
原文传递
导出
摘要 寻找非小细胞肺癌(NSCLC)独立的预后因素,识别手术后复发和死亡的高危险性病人,以指导临床治疗。方法随访NSCLC病人85例。采用组织学观察、免疫组织化学及聚合酶链反应-单链构象多态性(PCR-SSCP)方法和DNA图象分析技术,采用Cox回归模型,多变量分析了临床、病理及主要生物学等13项因素。结果本组病例中位随访时间为47个月;3年、5年总体生存率分别为66%和61%。Cox回归显示,早期复发和死亡的单变量预后因素(P<0.05)为:淋巴结状况、pTNM分期、瘤栓形成、微血管数目、Ki-67抗原标记率、DNA相对含量以及p53基因突变;其中微血管数目和pTNM分期(均P<0.01)为NSCLC独立的预后因素,并由此建立了NSCLC的复发和死亡预测模型,得出了预后指数(PI)。结论PI可能是临床评价病人预后、识别NSCLC手术后复发的高危险性病人很有实用价值的指标。 Objectives To find independent prognostic factor of non small cell lung cancer (NSCLC), identify the population with 'high risk' of recurrence and death in resected NSCLC, and direct adjuvant therapy for clinical doctors. Methods 85 resected patients from NSCLC were followed up. All patients were subjected to the study by light microscope, immunochemistry, PCR SSCP method, and DNA image analysis. Thirteen clinical, pathological, and biological factors were analysed by Cox regression model. Results The median follow up period was 47 months. The overall 3 year survival rate was 66% and the overall 5 year survival rate 61%. Cox regression showed significant univariate predictors ( P <0.05) of early recurrence and death for NSCLC were lymphnode status, pTNM, tumor emboli, microvessel count, Ki 67 antigen labeling, DNA relative content and p53 gene mutation. Microvessel count ( P <0.001) and pTNM ( P =0.006) were independent predictors of early recurrence and cancer death. According to the multivariate model for predicting early recurrence and cancer death, prognostic index (PI) was calculated. Conclusion The PI may be a useful clinical tool for evaluating prognosis of patients and identifying the population with 'high risk' of recurrence and death in NSCLC.
出处 《中华医学杂志》 CAS CSCD 北大核心 1997年第7期497-500,共4页 National Medical Journal of China
关键词 非小细胞肺癌 预后 COX模型 肺肿瘤 Non small cell lung cancer Prognosis Cox model
  • 相关文献

参考文献1

  • 1徐忠,上海医学,1992年,15卷,75页

同被引文献27

  • 1华新民,任宪伟,刘枫林,刘炀,张春江,李志杰,徐立,刘建阳,刘宇光.高剂量冲击式与低剂量密集式紫杉醇顺铂方案治疗非小细胞肺癌的对照研究[J].中华肿瘤杂志,2004,26(10):621-625. 被引量:17
  • 2许良中,朱雄增,蒋国梁,杜豫,朱伟萍,张泰明,金爱萍.203例肺癌癌基因与抗癌基因癌蛋白的研究[J].上海医科大学学报,1994,21(4):241-244. 被引量:14
  • 3冉瑞琼,傅晓颖,曹晓运,周决,曹世龙.P^(16)抑癌基因产物在肺癌中的表达及临床意义[J].上海医科大学学报,1997,24(2):83-86. 被引量:14
  • 4[2]Sozzi G,Musso K,Ratcliffe C,et al.Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients:a prospect for early diagnosis. Clin Cancer Res,1999,5(10):2689-2692.
  • 5[4]Boher JM, Pujol JL,Grenier J,et al.Markov model and markers of small cell lung cancer:assessing the influence of reversible serum NSE,CYFRA21-1 and TPS levels on prognosis.Br J Cancer,1999,79(9-10):1419-1427.
  • 6[5]Kim YC,Park KO,Kern JA,et al.The interactive effect of Ras,HER2,P53 and Bcl-2 express in predicting the survival of non-small cell lung cancer patients. Lung Cancer,1998,22(3):181-190.
  • 7[7]Kelly K,Mikhaeel-Kamel N.Medical treatment of lung cancer.J Thorac Imaging,1999,14(4):257-265.
  • 8[9]Stieber P,Zimmermann A,Reinmiedl J,et al. CYFRA21-1 in the early diagnosis of recurrent disease in non-small cell lung carcinomas (NSCLC). Anticancer Res,1999,19(4A):2865-8.
  • 9[10]Fracchia A,Ubbiali A,EI Bitar D,et al.Acomparative study on ferritin concentration in serum and bilateral bronchoalveolar lavage fluid of patients with peripheral lung cancer versus control subjects.Oncology,1999,56(3):181-8.
  • 10熊正文.免疫组织化学技术中抗原修复的研究进展[J].中华病理学杂志,1997,26(2):124-126. 被引量:74

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部